Medical Foods Market Growth, Global Survey, Analysis, Share, Company Profiles and Forecast by 2026 | Reports And Data

Medical Foods Market Size – USD 17.27 Billion in 2018, Industry Growth – CAGR of 6.9%, Industry Trends – Product Launches and Research for Advanced Tech Developments

Based on current analysis the global medical foods market was valued at USD 17.27 billion in 2018 and is expected to reach USD 29.54 billion by 2026, at a CAGR 6.9% Medical foods are planned for specific dietary management of a disease or a condition for which distinctive nutritional requirements, based on recognized scientific principles are established by medical evaluation. It is mandatory to consume medical foods under the supervision of a physician. Medical foods are to be consumed or administered enterally. Specially formulated and intended for the dietary management of a disease that has distinctive nutritional needs that cannot be met by normal diet alone are known to be medical foods. Medical foods are not required to undergo premarket review or approval by FDA. Besides, they are relieved from the labeling requirements for health claims and nutrient content claims under the Nutrition Labeling and Education Act of 1990. Medical foods are customized for both pediatric and adult use and are available in a variety of forms, including powders, liquids, capsules, tablets, and bars. Moreover, they are specialized blends of macronutrients, vitamins, minerals, phytochemicals, and botanicals or preparations composed of a single nutrient.

Leading Players Profiled in the Report Include:

Danone, Primus Pharmaceuticals, Inc., Nestlé, Abbott, Meiji Holdings and Co., Targeted Medical Pharma, Inc., Mead Johnson & Company, LLC., Accera, Inc., and Alfasigma.

The rising elderly population is a major driver for the global medical foods market. They are more likely to advance nutritional disorders as well as to fall prey to other diseases that affect their capacity to absorb nutrients from their diet. Nutrition deficiency disorders are also more common among the geriatric demographic than in other patient classes, leading to the elderly population becoming a key consumer sector for the global medical foods market. The increasing prevalence of diabetes across the world is another key driver for the global medical foods market.

Moreover, technological progressions have abridged the cost of enteral drug administration, making it profitable. North America is expected to dominate the market with a market share of xx% during the forecast period.

Key findings from the report

  • Due to high disease prevalence, diabetic neuropathy held the largest market share of 51.1% in 2018. Also, chronic kidney disorder is expected to emerge with the fastest CAGR of 6.6%
  • In the United States, Alzheimer is the 6thleading cause of death. An estimated 5.8 million Americans of all ages are living with Alzheimer’s dementia in 2019. This number includes an estimated 5.6 million people age 65 and older and roughly 200,000 individuals under age 65 who have younger-onset Alzheimer’s
  • Worldwide, 300 million people of all ages are suffering from depression. Depression is termed to be leading cause of disability around the world and is a key contributor to the overall global burden of disease
  • VAYA Pharma, Inc. introduced Vayarin Plus, extending its medical food offerings. The extra-strength formula in Vayarin, is indicated for the clinical dietary management of ADHD in adolescents and adults weighing over 97 lbs. Constant innovations and new product launches by leading manufacturers are the major factors boosting the demand for medical foods market
  • Orally administered medical foods accounted for the highest market share and are projected to maintain the dominance in future owing to ease in administration and their marketable probability. Enteral route of administration of medical foods registered highest CAGR and will continue to grow faster during the forecast period
  • Institutional sales of medical foods accounted the highest market revenue in the market while, online sales are expected to register the highest CAGR of 8.9% during the forecast period
  • North America is dominating the market with the largest market share of 44.0% due to technological developments, high prevalence of the target disease and overall awareness among the people to avoid further complexities caused by these diseases

Get a Sample Report PDF with Detail TOC & List of Figures @

Type (Revenue in USD Million; 2016–2026)

  • Pills and tablets
  • Powder
  • Others

Applications (Revenue in USD Million; 2016–2026)

  • Chronic kidney disease
  • Minimal hepatic encephalopathy
  • Chemotherapy-induced diarrhea
  • Pathogen-related infections
  • Diabetic neuropathy
  • ADHD
  • Depression
  • Alzheimer’s disease
  • Nutritional deficiency
  • Orphan diseases
    • Phenylketonuria
    • Eosinophilic esophagitis
    • FPIES
    • Others
  • Other

Route of Administration (Revenue in USD Million; 2016–2026)

  • Oral
  • Enteral

Sales Channel (Revenue in USD Million; 2016–2026)

  • Online Sales
  • Institutional Sales
  • Retail Sales

Regional Outlook (Revenue in USD Million; 2016–2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America
    • Brazil

Table of contents

Chapter 1. Market Synopsis

1.1. Market Definition

1.2. Research Scope & Premise

1.3. Methodology

1.4. Market Estimation Technique

Chapter 2. Executive Summary

2.1. Summary Snapshot, 2018 – 2026

Chapter 3. Indicative Metrics

3.1. Rising prevalence of chronic Applications

3.2. Customization of medical foods

3.3. Global burden of Alzheimer’s Application

3.4. Worldwide cases of depression

Chapter 4. Global Medical Foods Segmentation & Impact Analysis

4.1. Global Medical Foods Segmentation Analysis

4.2. Global Medical Food sMarket Value Chain Analysis, 2016-2026

4.3. Regulatory framework

4.4. Global Medical Foods Market Impact Analysis

4.4.1. Market driver analysis High prevalence of target Applications across the world Launch of variety of new products

4.4.2. Market restraint analysis Lack of awareness Availability of generics

4.5. Key opportunities prioritized

4.6. Global Medical Foods Pricing Analysis

4.7. Industry analysis – Porter’s

4.8. Global Medical Foods PESTEL Analysis


Chapter 11. Company Profiles

11.1. Danone

11.1.1. Company Overview

11.1.2. Financial Performance

11.1.3. Product Length Benchmarking

11.1.4. Strategic Initiatives

11.2. Primus pharmaceuticals

11.2.1. Company Overview

11.2.2. Financial Performance

11.2.3. Product Length Benchmarking

11.2.4. Strategic Initiatives

11.3. Nestle

11.3.1. Company Overview

11.3.2. Financial Performance

11.3.3. Product Length Benchmarking

11.3.4. Strategic Initiatives

11.4. Abbott

11.4.1. Company Overview

11.4.2. Financial Performance

11.4.3. Product Length Benchmarking

11.4.4. Strategic Initiatives

11.5. Meiji holdings

11.5.1. Company Overview

11.5.2. Financial Performance

11.5.3. Product Length Benchmarking

11.5.4. Strategic Initiatives

11.6. Targeted medical pharma

11.6.1. Company Overview

11.6.2. Financial Performance

11.6.3. Product Length Benchmarking

11.6.4. Strategic Initiatives

11.7. Mead johnson

11.7.1. Company Overview

11.7.2. Financial Performance

11.7.3. Product Length Benchmarking

11.7.4. Strategic Initiatives

11.8. Accera

11.8.1. Company Overview

11.8.2. Financial Performance

11.8.3. Product Length Benchmarking

11.8.4. Strategic Initiatives

11.9. Alfasigma

11.9.1. Company Overview

11.9.2. Financial Performance

11.9.3. Product Length Benchmarking

11.9.4. Strategic Initiatives

Request for Customization @

Thank you for reading our report. In case of further queries regarding the report or inquiry about its customization, please connect with us. We will ensure your report is well-suited to your requirements.

Leave a comment

Your email address will not be published. Required fields are marked *